In vivo synergistic cytogenetic effects of aminophylline on lymphocyte cultures from patients with lung cancer undergoing chemotherapy

Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis

Volumn 740, Issue 1-2, 2012, Pages 1-5

  Mylonaki, Effie ^a   Manika, Katerina ^a   Zarogoulidis, Paul ^a   Domvri, Kalliopi ^a   Voutsas, Vasilis ^a   Zarogoulidis, Kostas ^a   Mourelatos, Dionysios ^a  

^a ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

Author keywords

Aminophylline; Non small cell lung cancer; Proliferation rate index; Sister chromatid exchange; Small cell lung cancer; Synergism

Indexed keywords

AMINOPHYLLINE; ANTINEOPLASTIC AGENT; CARBOPLATIN; ETOPOSIDE; GESIDIN; IFOSFAMIDE; MITOMYCIN; UNCLASSIFIED DRUG; VINTESINE;

ADULT; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER LOCALIZATION; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOGENETICS; DRUG EFFECT; DRUG EFFICACY; DRUG POTENTIATION; DRUG RESPONSE; DRUG SCREENING; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LUNG NON SMALL CELL CANCER; LUNG SMALL CELL CANCER; LYMPHOCYTE CULTURE; LYMPHOCYTE PROLIFERATION; PRIORITY JOURNAL; SISTER CHROMATID EXCHANGE;

AMINOPHYLLINE; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; CARCINOMA, SMALL CELL; CELLS, CULTURED; DRUG SYNERGISM; FEMALE; HISTORY, MEDIEVAL; HUMANS; LUNG NEOPLASMS; LYMPHOCYTES; MALE; MIDDLE AGED; SISTER CHROMATID EXCHANGE;

EID: 84871388788     PISSN: 00275107     EISSN: 09218262     Source Type: Journal    
DOI: 10.1016/j.mrfmmm.2012.10.002     Document Type: Article

References (41)

1. Parkin D.M., Bray F., Ferlay J., Pisani P. Global cancer statistics, 2002. CA Cancer J. Clin. 2005, 55:74-108.
2. Jemal A., Bray F., Center M.M., Ferlay J., Ferlay J., Ward E., Forman D. Global cancer statistics. CA Cancer J. Clin. 2011, 61:69-90.
3. Mirsadraee S., Oswal D., Alizadeh Y., Caulo A., van Beek E.J. The 7th lung cancer TNM classification and staging system: review of the changes and implications. World J. Radiol. 2012, 4:128-134.
4. Thatcher N., Heighway J. Maintenance and consolidation therapy in patients with unresectable stage III/IV non-small cell lung cancer. Oncologist 2010, 15:1034-1042.
5. Nieder C., Pawinski A., Dalhaug A., Andratschke N. A review of clinical trials of cetuximab combined with radiotherapy for non-small cell lung cancer. Radiat. Oncol. 2012, 7:3.
6. Baka S., Ekonomopoulou M.T., Kosmidis C., Efthimiadis C., Iakovidou-Kritsi Z. Cytogenetic effects of recombinant interferon-gamma on lymphocytes cultures from patients with non-small cell lung cancer. Cancer Genet. Cytogenet. 2009, 193:38-43.
7. Akritopoulou K., Iakovidou-Kritsi Z., Mioglou-Kalouptsi E., Ekonomopoulou M.T., Mourelatos D. Cytogenetic activity of diazepam in normal human lymphocyte cultures. Genet. Test Mol. Biomarkers 2009, 13:227-231.
8. Tofilon P.J., Basic I., Milas L. Prediction of in vivo tumor response to chemotherapeutic agents by the in vitro sister chromatid exchange assay. Cancer Res. 1985, 45:2025-2030.
9. Deen D.F., Kendall L.E., Marton L.J., Tofilon P.J. Prediction of human tumor cell chemosensitivity using the sister chromatid exchange assay. Cancer Res. 1986, 46:1599-1602.
10. Papageorgiou A., Tsavdaridis D., Geromichalos G.D., Camoutsis C., Karaberis E., Mourelatos D., Chrysogelou E., Houvartas S., Kotsis A. A comparative study on cytogenetic and antineoplastic effects induced by two modified steroidal alkylating agents. Cancer Detect. Prev. 2001, 25:369-374.
11. Papageorgiou A., Mourelatos C., Geromichalos G., Geromichalou E., Dalezis P., Lialiaris T. Antitumour and cytogenetic effects of modified steroidal derivatives of propenoic acid: in vivo/in vitro studies. Anticancer Res. 2010, 30:4201-4204.
12. Mylonaki-Charalambours E., Mourelatos D., Kotsis A. A comparative study of the cytogenetic and antineoplasmatic effects induced by carboplatin in combination with niacin in human lymphocytes in vitro and in Ehrlich ascites tumor cells in vivo. Chemotherapy 1998, 44:121-128.
13. Lialiaris T., Lyratzopoulos E., Papachristou F., Simopoulou M., Mourelatos C., Nikolettos N. Supplementation of melatonin protects human lymphocytes in vitro from the genotoxic activity of melphalan. Mutagenesis 2008, 23:347-354.
14. Mourelatos D., Mylonaki E., Papageorgiou A., Boutis L., Paradelis A., Anastasiou A., Catsoulacos P. Comparative study of SCE induction and cytostatic effects by homo-azasteroidal esters of N,N-bis(2-chloroethyl)aminobenzoic acid in human lymphocytes. Mutat. Res. 1995, 346:129-133.
15. Hirsh L., Dantes A., Suh B.S., Yoshida Y., Hosokawa K., Tajima K., Kotsuji F., Merimsky O., Amsterdam A. Phosphodiesterase inhibitors as anti-cancer drugs. Biochem. Pharmacol. 2004, 68:981-988.
16. Aminophylline Professional Monograph, 2012.
17. Youdim K.A., Qaiser M.Z., Begley D.J., Rice-Evans C.A., Abbott N.J. Flavonoid permeability across an in situ model of the blood-brain barrier. Free Radic. Biol. Med. 2004, 36:592-604.
18. Murata J., Ayukawa K., Ogasawara M., Watanabe H., Saiki I. Induction of autocrine factor inhibiting cell motility from murine B16-BL6 melanoma cells by alpha-melanocyte stimulating hormone. Int. J. Cancer 1999, 80:889-895.
19. Timoshenko A.V., Xu G., Chakrabarti S., Lala P.K., Chakraborty C. Role of prostaglandin E2 receptors in migration of murine and human breast cancer cells. Exp. Cell Res. 2003, 289:265-274.
20. Santibanez J.F., Olivares D., Guerrero J., Martinez J. Cyclic AMP inhibits TGFbeta1-induced cell-scattering and invasiveness in murine-transformed keratinocytes. Int. J. Cancer 2003, 107:715-720.
21. Yamanaka Y., Mammoto T., Kirita T., Mukai M., Mashimo T., Sugimura M., Kishi Y., Nakamura H. Epinephrine inhibits invasion of oral squamous carcinoma cells by modulating intracellular cAMP. Cancer Lett. 2002, 176:143-148.
22. Shafer S.H., Phelps S.H., Williams C.L. Reduced DNA synthesis and cell viability in small cell lung carcinoma by treatment with cyclic AMP phosphodiesterase inhibitors. Biochem. Pharmacol. 1998, 56:1229-1236.
23. Merimsky O., Hirsh L., Dantes A., Land-Bracha A., Suh B.S., Amsterdam A. Induction of apoptosis in non-small lung carcinoma cell line (H1299) by combination of anti-asthma drugs with gemcitabine and cisplatin. Int. J. Oncol. 2005, 26:475-482.
24. Clare M.G., Taylor J.H., Blain E., Jones W.G. The quantitation of sister chromatid exchanges in lymphocytes of cancer patients at intervals after cytotoxic chemotherapy. Eur. J. Cancer Clin. Oncol. 1983, 19:1509-1515.
25. Mourelatos D., Kourakis A., Dozi-Vassiliades J., Tsiouris J., Hatzitheodoridou P. Synergistic induction of sister-chromatid exchanges in lymphocytes from normal subjects and from patients under cytostatic therapy by inhibitors of poly(ADP-ribose)polymerase and antitumour agents. Mutat. Res. 1985, 143:225-230.
26. Mourelatos D. Chromosomes study as predictor of chemoresponse of tumours. Cancer J. 1996, 9:136-141.
27. Banner K.H., Page C.P. Immunomodulatory actions of xanthines and isoenzyme selective phosphodiesterase inhibitors. Monaldi Arch. Chest Dis. 1995, 50:286-292.
28. Bernini J.C., Fort D.W., Griener J.C., Kane B.J., Chappell W.B., Kamen B.A. Aminophylline for methotrexate-induced neurotoxicity. Lancet 1995, 345:544-547.
29. Hussein A., Al-Wadei N., Takahashi T., Schuller H.M. Theophylline stimulates cAMP-mediated signaling associated with growth regulation in human cells from pulmonary adenocarcinoma and small airway epithelia. Int. J. Oncol. 2005, 27:155-160.
30. Lentini A., Vidal-Vanaclocha F., Facchiano F., Caraglia M., Abbruzzese A., Beninati S. Theophylline administration markedly reduces hepatic and pulmonary implantation of B16-F10 melanoma cells in mice. Melanoma Res. 2000, 10:435-443.
31. Lentini A., Tabolacci C., Mattioli P., Provenzano B., Beninati S. Antitumor activity of theophylline in combination with Paclitaxel: a preclinical study on melanoma experimental lung metastasis. Cancer Biother. Radiopharm. 2010, 25:497-503.
32. Lentini A., Tabolacci C., Nardi A., Mattioli P., Provenzano B., Beninati S. Preclinical evaluation of the antineoplastic efficacy of 7-(2-hydroxyethyl)theophylline on melanoma cancer cells. Melanoma Res. 2012, 22:133-139.
33. Kizawa Y., Furuya M., Saito K., Masuko T., Kusama T. Effects of dexamethasone and aminophylline on survival of Jurkat and HL-60 cells. Biol. Pharm. Bull. 2006, 29:281-285.
34. Yoshida Y., Hosokawa K., Dantes A., Tajima K., Kotsuji F., Amsterdam A. Theophylline and cisplatin synergize in down regulation of BCL-2 induction of apoptosis in human granulosa cells transformed by a mutated p53 (p53 val135) and Ha-ras oncogene. Int. J. Oncol. 2000, 17:227-235.
35. Day P., Shalaby Z., Cohen M.M., Wasserman S.S., Schwartz S. Effects of theophylline on chromosomal breakage and sister-chromatid exchange. Mutat. Res. 1989, 224:409-413.
36. Giri A.K., Das M., Reddy V.G., Pal A.K. Mutagenic and genotoxic effects of theophylline and theobromine in Salmonella assay and in vivo sister chromatid exchanges in bone marrow cells of mice. Mutat. Res. 1999, 444:17-23.
37. Mourelatos D., Dozi-Vassiliades J., Granitsas A. Anti-tumour alkylating agents act synergistically with methylxanthines on induction of sister-chromatid exchange in human lymphocytes. Mutat. Res. 1982, 104:243-247.
38. Mourelatos D., Dozi-Vassiliades J., Tsigalidou-Balla V., Granitsas A. Enhancement by methylxanthines of sister-chromatid exchange frequency induced by cytostatics in normal and leukemic human lymphocytes. Mutat. Res. 1983, 121:147-152.
39. Fingert H.J., Boorstein R.J., Kindy R.L., Lau C.C. Differential enhanced lethality by caffeine in human cancer cells and normal cells treated with alkylating agents. Proceedings of the American Association for Cancer Research 1983, p. 270.
40. Fingert H.J., Chang J.D., Pardee A.B. Cytotoxic cell cycle, and chromosomal effects of methylxanthines in human tumor cells treated with alkylating agents. Cancer Res. 1986, 46:2463-2467.
41. Ishii B.M. Y Caffeine inhibition of prereplication repair of mitomycin C-induced DNA damage in human peripheral lymphocytes. Mutat. Res. 1978, 51:419-425.